These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26836778)

  • 21. Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.
    Akher FB; Farrokhzadeh A; Ramharack P; Shunmugam L; Van Heerden FR; Soliman MES
    Med Hypotheses; 2019 Nov; 132():109359. PubMed ID: 31466018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
    Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
    J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase.
    Di Francesco ME; Avolio S; Pompei M; Pesci S; Monteagudo E; Pucci V; Giuliano C; Fiore F; Rowley M; Summa V
    Bioorg Med Chem; 2012 Aug; 20(15):4801-11. PubMed ID: 22770556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase.
    Khalid H; Landry KB; Ijaz B; Ashfaq UA; Ahmed M; Kanwal A; Froeyen M; Mirza MU
    Infect Genet Evol; 2020 Oct; 84():104371. PubMed ID: 32485331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.
    Hendricks RT; Fell JB; Blake JF; Fischer JP; Robinson JE; Spencer SR; Stengel PJ; Bernacki AL; Leveque VJ; Le Pogam S; Rajyaguru S; Najera I; Josey JA; Harris JR; Swallow S
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3637-41. PubMed ID: 19447623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined 3D-QSAR, molecular docking and molecular dynamics study on the benzimidazole inhibitors targeting HCV NS5B polymerase.
    Wang Z; Chen Z; Li J; Huang J; Zheng C; Liu JP
    J Biomol Struct Dyn; 2020 Mar; 38(4):1071-1082. PubMed ID: 30915896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.
    Kaushik-Basu N; Bopda-Waffo A; Talele TT; Basu A; Costa PR; da Silva AJ; Sarafianos SG; Noël F
    Nucleic Acids Res; 2008 Mar; 36(5):1482-96. PubMed ID: 18203743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
    Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.
    Golub AG; Gurukumar KR; Basu A; Bdzhola VG; Bilokin Y; Yarmoluk SM; Lee JC; Talele TT; Nichols DB; Kaushik-Basu N
    Eur J Med Chem; 2012 Dec; 58():258-64. PubMed ID: 23127989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.
    Mish MR; Cho A; Kirschberg T; Xu J; Zonte CS; Fenaux M; Park Y; Babusis D; Feng JY; Ray AS; Kim CU
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3092-5. PubMed ID: 24907145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.
    Stammers TA; Coulombe R; Duplessis M; Fazal G; Gagnon A; Garneau M; Goulet S; Jakalian A; LaPlante S; Rancourt J; Thavonekham B; Wernic D; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6879-85. PubMed ID: 24176401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.
    Dryer PD; Limketkai BN; Martin CM; Ma G; Sherman KE; Taylor LE; Mayer KH; Jamieson DJ; Blackard JT
    J Antimicrob Chemother; 2009 Nov; 64(5):945-8. PubMed ID: 19767319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
    Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.
    Tomei L; Altamura S; Paonessa G; De Francesco R; Migliaccio G
    Antivir Chem Chemother; 2005; 16(4):225-45. PubMed ID: 16130521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
    J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; Omar FA
    Eur J Med Chem; 2019 Dec; 184():111747. PubMed ID: 31604164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.
    Nie B; Guo Y; Zhang K; Liu J; Yun S
    Arch Virol; 2020 Sep; 165(9):2013-2020. PubMed ID: 32601956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure.
    Yan S; Larson G; Wu JZ; Appleby T; Ding Y; Hamatake R; Hong Z; Yao N
    Bioorg Med Chem Lett; 2007 Jan; 17(1):63-7. PubMed ID: 17049849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.